← Pipeline
Registered human trialRecruitingNo efficacy data yet
Phase 1/2
ReVIVE
Clemastine • chronic demyelination
Practical availability: Research study — recruiting does not guarantee access
- Compound / intervention
- Clemastine • chronic demyelination
- Mechanism
- Clemastine; muscarinic-receptor antagonism
- Development stage
- Phase 1/2
- Status
- Recruiting
- Population / locations
- Site: UCSF, US • no Greek site
- Evidence level
- Human Phase 1/2 • results pending
Next substantive checkpoint
Multiparametric MRI for changes in myelin • estimated completion 2027
Related substantive developments
No separate substantive update is currently linked.